Repligen Corp (NASDAQ:RGEN)
| 157.10 Delayed Data As of Nov 30 |  -2.24 / -1.40%Today’s Change | 110.45 Today|||52-Week Range 200.98 | -7.21% Year-to-Date |
Latest RGEN News | Press Releases
| Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue? Nov 30 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 159.49 |
| Today’s open | 159.12 |
| Day’s range | 156.06 - 161.00 |
| Volume | 712,429 |
| Average volume (3 months) | 581,806 |
| Market cap | $9.0B |
Data as of 4:00pm ET, 11/30/2023
Growth & Valuation
| Earnings growth (last year) | +43.79% |
| Earnings growth (this year) | -29.61% |
| Earnings growth (next 5 years) | -5.00% |
| Revenue growth (last year) | +19.54% |
| P/E ratio | 77.4 |
| Price/Sales | 12.14 |
| Price/Book | 4.70 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SRPTSarepta Therapeutics... | +0.88 | +1.09% |
| JAZZJazz Pharmaceuticals... | +3.97 | +3.47% |
| KRTXKaruna Therapeutics ... | +2.63 | +1.39% |
| IONSIonis Pharmaceutical... | +0.06 | +0.12% |
Data as of 4:00pm ET, 11/30/2023
Financials
| Next reporting date | February 15, 2024 |
| EPS forecast (this quarter) | $0.65 |
| Annual revenue (last year) | $801.5M |
| Annual profit (last year) | $186.0M |
| Net profit margin | 23.20% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Waltham, Massachusetts |
Forecasts
